1. Home
  2. EQBK vs CGEM Comparison

EQBK vs CGEM Comparison

Compare EQBK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

HOLD

Current Price

$44.93

Market Cap

932.4M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.21

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQBK
CGEM
Founded
2002
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.4M
904.7M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
EQBK
CGEM
Price
$44.93
$14.21
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
$51.33
$30.13
AVG Volume (30 Days)
73.0K
827.4K
Earning Date
04-14-2026
05-11-2026
Dividend Yield
1.59%
N/A
EPS Growth
N/A
N/A
EPS
0.80
N/A
Revenue
N/A
N/A
Revenue This Year
$74.58
N/A
Revenue Next Year
$5.11
$5.20
P/E Ratio
$56.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.04
$5.68
52 Week High
$50.07
$16.74

Technical Indicators

Market Signals
Indicator
EQBK
CGEM
Relative Strength Index (RSI) 46.77 46.16
Support Level $44.41 $13.75
Resistance Level $46.99 $16.10
Average True Range (ATR) 0.86 1.05
MACD -0.11 0.02
Stochastic Oscillator 30.99 38.92

Price Performance

Historical Comparison
EQBK
CGEM

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: